C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria  by Rangan, Gopala K. et al.
Kidney International, Vol. 67 (2005), pp. 492–503
C5b-9 does not mediate chronic tubulointerstitial disease in the
absence of proteinuria
GOPALA K. RANGAN, JEFFREY W. PIPPIN, JASON D. COOMBES, and WILLIAM G. COUSER
Division of Nephrology, University of Washington Medical Center, Seattle, Washington; and Kidney Regeneration Laboratory,
Centre for Transplant and Renal Research, Westmead Millennium Institute, The University of Sydney at Westmead Hospital,
Sydney, Australia
C5b-9 does not mediate chronic tubulointerstitial disease in the
absence of proteinuria.
Background. In nephrotic glomerular diseases, the intratubu-
lar assembly of the membrane attack complex (C5b-9) is one
of the principal mediators of chronic tubulointerstitial damage.
Here, we examined whether C5b-9 has a pathogenic role in
tubulointerstitial disease in the absence of proteinuria.
Methods. Three pathophysiologically distinct models of non-
proteinuric chronic tubulointerstitial disease were induced in
Piebald-Viral-Glaxo (PVG) rats, with or without C6 deficiency
(C6+ and C6): (1) unilateral ureteric obstruction (UUO, days
1, 3, 6, 14, and 21; N = 5–6/group); (2) cyclosporine (CsA)
nephropathy (15 mg/kg SC daily with 0.05% sodium diet; day
14, 35 N = 9/group); and (3) streptozotocin (STZ)-induced di-
abetes (day 90, N = 8/group).
Results. The peritubular deposition of C5b-9 increased in all
three models. In UUO, the number of vimentin-positive tubules,
interstitial volume expansion, and monocyte accumulation were
similar in both the C6+ and C6− groups at all time points. There
was a trend toward an earlier peak in myofibroblast accumula-
tion in C6− rats with UUO (d3 vs. d6; P = 0.05), but this did not
prevent fibrosis at later time points. In CsA nephropathy, corti-
cal tubulointerstitial damage was also similar in both C6+ and
C6− groups on day 14, despite equivalent CsA trough levels. Fi-
nally, in STZ-induced diabetes, rats did not develop proteinuria,
and tubulointerstitial disease (distal tubule glycogen nephrosis,
interstitial volume expansion, and tubular dilatation) was not
altered by C6 deficiency.
Conclusion. These data suggest that, in contrast to protein-
uric states, C5b-9 does not have a significant impact on the pro-
gression of tubulointerstitial damage in nonproteinuric chronic
renal disease.
In human chronic glomerular disease, the severity of
tubular atrophy and interstitial disease is the strongest
histologic parameter that correlates with renal func-
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tion and predicts progression [1]. Irreversible damage
to the glomerular capillary wall and ultrafiltration of
serum-derived proteins into the tubular lumen is one of
the nonimmunologic mechanisms that evoke secondary
tubulointerstitial disease, a process that is independent
of the original inciter(s) of glomerular injury [2, 3]. Over
the last two decades, substantial clinical [4–12] and exper-
imental [12–21] evidence has accumulated to support the
hypothesis that the abnormal presence of serum-derived
complement components in the tubular lumen during
proteinuric states leads to the assembly of the sublytic
terminal membrane attack complex (C5b-9) on the brush
border of tubular epithelial cells (TECs), and this is an im-
portant factor in the causation of tubulointerstitial dam-
age in proteinuric renal diseases [22, 23].
In previous studies, we examined the progression
of tubulointerstitial damage in three animal models of
nonimmune-mediated chronic proteinuric renal disease
(puromycin aminonucleoside, the remnant kidney model,
and adriamycin nephropathy) using rats unable to gen-
erate C5b-9 due to the absence of the C6 complement
component [19, 21, 24]. In these models, C5b-9 was lo-
calized to the lumen and brush border of TECs [19, 21].
Consistently, in all three proteinuric models, tubulointer-
stitial injury was attenuated in C6-deficient rats compared
to the C6 replete group, despite equivalent proteinuria
and uremia. In the remnant kidney model, C6 deficiency
was even associated with regression of early renal injury
[21].
However, whether C5b-9 plays a functional role in me-
diating chronic tubulointerstitial disease in the absence
of proteinuria is not known. In humans with obstructive
uropathy and pyelonephritis, the deposition of peritubu-
lar C5b-9 was increased in the renal cortex [5]. Moreover,
acute tubulointerstitial injury induced by renal ischemia
was suppressed in mice deficient in the C6 component of
complement [24]. These data indicate that C5b-9 could
also mediate tubulointerstitial damage in nonprotein-
uric chronic renal diseases. On the other hand, TECs
might be more resistant to chronic attack by C5b-9 on
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the basolateral side due to the constitutive expression of
membrane-bound complement inhibitors in the intersti-
tium [26, 27]. The aim of this study was to test the hy-
pothesis that, in the absence of proteinuria, C5b-9 is not
an important mediator of tubulointerstitial damage. To
test this hypothesis, three nonimmune-mediated and non-
proteinuric models of chronic tubulointerstitial disease
(unilateral ureteric obstruction, cyclosporine nephropa-
thy, and early streptozotocin-induced diabetes) were in-
duced in Pieblold-Viral-Glaxo (PVG) rats with or without
C6 deficiency.
METHODS
Animals
PVG rats with or without C6 deficiency were obtained
from the breeding colony at the University of Wash-
ington, Seattle, Washington. The original source for the
breeding pairs with normal complement activity was Har-
lan Sprague-Dawley (Cambridge, UK), and that for the
C6-deficient animals was Bantin and Kingman Univer-
sal (Edmonds, WA, USA) [19, 21]. Before the study,
the hemolytic activity in serum from each rat was mea-
sured by a standard CH50 assay [28]. Complement ac-
tivity was not detected in C6-deficient animals. All rats
were housed in groups of two to three per cage and al-
lowed free access to a standard commercial diet and tap
water, unless otherwise stated in the specific experimen-
tal models. Experimental protocols were approved by the
Animal Use Care Committee of the University of Wash-
ington and conducted in accordance with the National
Institutes of Health Guide for the Use and Care of Labo-
ratory Animals.
Experimental models
Unilateral ureteric obstruction (UUO). Complete
UUO was performed in adult female animals aged
3 months and weighing 189 ± 2 g (total N = 62, C6+
N = 31 and C6− N = 31) [29]. The rats were anesthetized
with a single injection of ketamine and xylazine (90 mg/kg
and 10 mg/kg). The right kidney and ureter were exposed
via a midline incision. The right ureter was ligated with
5–0 silk at two points and cut between the ligatures in
order to prevent retrograde urinary tract infection. The
incision was closed with 4–0 absorbable suture (muscle
layer) and surgical staples (skin). There were a total of 4
deaths in the perioperative period (3 C6+ and 1 C6−).
Surviving animals were sacrificed on days 1, 3, 6, 14, and
24 after induction of obstruction (N = 5–6 per time point
per group).
Cyclosporine (CsA) nephropathy. CsA nephropathy
was induced in adult male littermates (aged 2 months,
mean body weight 236 ± 1 g; total N = 48; C6+ N =
24 and C6− N = 24) using a protocol previously de-
scribed in our laboratory for Sprague-Dawley rats [30].
Rats were fed a low sodium diet (0.05% sodium; Teklad
Premier, Madison, WI, USA) to potentiate tubulointer-
stitial injury in CsA nephropathy [30]. After one week on
a low sodium diet, weight-matched rats were randomly
assigned to either CsA administration (15 mg/kg SC daily;
Sandimmune Injection, Novartis Pharmaceuticals Cor-
poration, East Hanover, NJ, USA) or an equivalent dose
of vehicle (olive oil). Preliminary experiments confirmed
that this dose of CsA was sufficient to induce tubulointer-
stitial damage in C6+ PVG rats. Groups were sacrificed
and renal tissue was obtained on days 14 and 35 (N = 9
C6+ and C6− per CsA group and N = 6 C6+/C6− per
control group and time point).
Streptozotocin (STZ)-induced diabetic mellitus. Dia-
betes mellitus was induced in adult male littermates (aged
3 months, total N = 29; mean body weight 305 ± 3 g C6+
N = 21; C6− N = 8) by subcutaneous injections of freshly
prepared STZ (Sigma, St. Louis, MO, USA) at a dose of 40
mg/kg in ice-cold 0.5 mol/L sodium citrate buffer (pH 4.5).
A second injection (40 mg/kg) was administered 24 hours
later [31]. This method produces diabetes in more than
95% of animals without inducing acute renal failure or
death due to hypoglycemia (secondary to insulin release
associated with acute b-cell destruction) [31], and this was
confirmed in preliminary studies. Forty-eight hours after
the second injection, a subgroup of C6+ STZ-injected an-
imals (N = 7), matched by weight and blood glucose lev-
els, underwent subcutaneous implantation of a single (7 ×
2 mm) sustained release insulin pellet (Linplant; Linshin
Canada, Scarborough, Ontario, Canada) over the dorsal
neck, as recommended by the manufacturer. The pellet
releases regular insulin at a constant rate of 2 units per day
for 60 days or longer [32]. In preliminary studies, one pel-
let was sufficient to maintain normoglycemia in PVG rats
with STZ-induced diabetes. A group of C6+animals (N =
6) received injections of citrate buffer only, and served
as the control group. The STZ injections and implanta-
tion of the insulin pellets were performed under ether
anesthesia. Whole blood glucose was measured at multi-
ple time points by glucometer (One Touch Blood Glu-
cose Meter; Lifescan Incorporated, Milpitas, CA, USA)
readings of glucose oxidase test strips (One Touch Test
Strips; Lifescan Incorporated) using tail-vein blood. Uri-
nary ketones were measured intermittently by dipstick
analysis (Ketostix Reagent Strips; Bayer Corporation,
Elkart, IN, USA). Groups of animals were sacrificed on
day 90. The study was not extended beyond this time
point because untreated diabetic animals progressively
lost weight.
Renal function
Rats were placed in metabolic cages for 16 hours on the
day before sacrifice. Urinary protein was measured by the
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sulfosalicylic acid method. In the CsA study, trough CsA
levels were measured from whole blood at the time of sac-
rifice, using a high-performance liquid chromatography
(HPLC) method (Pathology Department, University of
Washington Medical Center). Serum urea and creatinine
were measured by an autoanalyzer (Hitachi B747; Insti-
tute of Clinical Pathology and Medical Research, West-
mead Hospital, Sydney, NSW, Australia).
Renal histology and immunohistochemistry
Coronal sections of the kidney were immersion-fixed
in methyl Carnoy’s solution, dehydrated through graded
alcohols, and embedded in paraffin. Sections 4 lm in
thickness were stained with periodic acid-Schiff (PAS),
Masson’s trichrome, or used for immunohistochemistry.
For immunohistochemistry, tissue sections were de-
paraffinized with Histoclear (National Diagnostics,
Atlanta, GA, USA) and rehydrated. Endogenous
peroxidase activity was quenched with 3% hydrogen
peroxide for 10 minutes, followed by incubation with a
blocking agent (Background Buster; Accurate Chemi-
cal & Scientific Corporation, Westbury, NY, USA). The
kidney sections were then incubated with either of the
following primary and secondary antibodies: (1) a mon-
oclonal mouse (ED-1) IgG1 antibody reactive against
rat monocytes and macrophages (1:400; Serotec, UK)
at 4◦C overnight, followed by a biotinylated rabbit an-
timouse IgG1 antibody (1:400; all secondary antibod-
ies were from Zymed Laboratories, San Francisco, CA,
USA, unless otherwise stated); (2) a mouse antibody
reactive against a-smooth muscle actin (a-SMA) clone
1A4 (1:4000; Sigma-Aldrich, St. Louis, MO, USA) at
4◦C overnight, followed by a biotinylated rabbit anti-
mouse IgG2a antibody (1:400); (3) a murine monoclonal
IgG antibody V9 reactive against vimentin (1:100; Dako,
Carpinteria, CA, USA) at 4◦C overnight, followed by
a peroxidase monoclonal rat antimouse IgGa antibody
(1:100); (4) a polyclonal goat antibody reactive against rat
type IV collagen (1:600; Southern Biotechnology, Birm-
ingham, AL, USA) at 4◦C overnight, followed by a bi-
otinylated rabbit antigoat IgG antibody (1:400); (5) a
rabbit antibody reactive against rat fibronectin (affin-
ity purified) (1:500; Chemicon International, Temecula,
CA, USA) at 4◦C overnight, followed by a biotinylated
goat-antirabbit IgG antibody (1:400); (6) a mouse anti-
body reactive against rat proliferating cell nuclear antigen
(PCNA, 1:100; clone PC10, Dako, Sydney, Australia), fol-
lowed by a biotinylated rabbit antimouse IgG2a antibody.
Immunoreactivity of the tissue sections was visualized
with Vectastain Elite ABC reagent (Vector Laborato-
ries, Burlingame, CA, USA) and DAB (Sigma-Aldrich).
As a negative control for nonspecific immunoreactivity,
preimmune serum (from the same animal species as the
primary antibody) was substituted in place of the primary
antibody, with each staining procedure. The slides were
counterstained with 2% methylgreen.
Tissue for immunofluorescence was embedded in
OCT compound (Lab-Tek products; Miles Laboratories,
Naperville, IL, USA) and snap-frozen in liquid nitrogen.
The presence of rat C5b-9 was determined using biotiny-
lated antirat C5b-9 monoclonal antibody 2A1 (UUO
study), as previously described [19, 21, 24] or rabbit an-
tihuman C5b-9 (1:50 for 1 hour at room temperature;
Calbiochem, La Jolla, CA, USA) (CsA and STZ stud-
ies), followed by biotinylated goat antirabbit antibody
(1:200; Zymed Laboratories) and then FITC-streptavidin
(Amersham, Sydney, Australia) [28]. Phosphate-buffered
saline was substituted for the primary antibody as a neg-
ative control.
Quantitative and semiquantitative analysis of
tubulointerstitial damage
Both quantiative and semiquantitative analysis of
tubulointerstitial damage was performed on PAS
sections, as previously described [24, 34]. A uniformly
random cluster method was used to determine the micro-
scopic fields for evaluation [35]. Five points were marked
circumferentially around the coronal section with a fine-
point marking pen. A midcortical field (×400), adjacent
to each pen mark, which contained tubular structures
only, was evaluated for analysis. For quantitative analysis,
the cross-sectional diameter and cell height of tubules in
the selected cortical field, as well as interstitial volume,
were measured by line and area computer morphometric
measurements, respectively, from digital images (Olym-
pus BX51 scientific microscope and DP 11 digital camera;
Olympus Optical Co. Ltd., Tokyo, Japan) and image anal-
ysis software (Optimas version 6.57; Media Cybernetics,
Silver Spring, MD, USA), as previously described [35].
For semiquantitative analysis (UUO study only),
tubular injury (defined as tubular atrophy, dilatation,
and thickening of the basement membrane), intersti-
tial inflammation, and interstitial fibrosis (blue stain in
Trichome-stained sections) were each assessed separately
[8, 9]. Ten cortical fields from each animal were exam-
ined at ×200 magnification using a graticule (0.5 mm2),
and graded according to a scale of 0 to 4: 0, no tubu-
lar injury, interstitial inflammation or absent interstitial
collagen deposition; 1, <25% of tubules injured, mini-
mal interstitial inflammation, or deposition of interstitial
collagen (<25%); 2, 25% to 50% of tubules injured or
mild interstitial inflammation or deposition of interstitial
collagen (25–50%); 3, 51% to 75% of tubules injured,
moderate interstitial inflammation or deposition of inter-
stitial collagen (50–75%); and 4, 76% to 100% of tubules
injured, diffuse interstitial inflammation, or deposition of
interstitial collagen (>75%).
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The number of cortical and medullary vimentin-
positive tubules, interstitial ED-1 positive cells, and
PCNA positive tubules (cortex only), were counted in 10
randomly selected fields (×400), using a 10 × 10 optical
grid, and expressed as vimentin-positive tubules or ED-1
positive interstitial cells per high power field, or PCNA
positive tubules per mm2. A tubule was defined as posi-
tive for vimentin if it contained one or more immunore-
active tubular epithelial cells. The percentage area of
positive staining for interstitial a-SMA, fibronectin, and
type IV collagen deposition were assessed by quantita-
tive image analysis in 10 cortical or medullary fields, as
previously described [19, 21].
Statistics
Data are expressed as mean ± SE. Comparisons be-
tween experimental groups were performed using the in-
dependent t test for parametric data, and Kruskal-Wallis
test for nonparametric data. Tests to determine the distri-
bution of data and all other calculations were performed
using statistical software (JMP version 4.04; SAS Insti-
tute, Cary, NC, USA). P < 0.05 was defined as statistically
significant.
RESULTS
Unilateral ureteric obstruction
C5b-9 immunofluorescence. C5b-9 deposition in-
creased in the tubulointerstitial compartment of C6+ rats
with UUO, in a time-dependent manner (Fig. 1). The in-
crease was most marked between days 14 and 24, when
there was a dramatic elevation in C5b-9 expression in
the basolateral membranes of tubules. By day 24, C5b-
9 immunofluorescence appeared as ribbon-like deposits
around tubules. C5b-9 was not detected in C6-deficient
animals.
Tubular injury and interstitial inflammation. The
weight (corrected for body weight) of obstructed kid-
neys increased in C6+ rats, peaking on day 6 and sub-
sequently decreasing. This time course was not altered
by C6 deficiency (Fig. 2). By light microscopy, rats with
UUO developed progressive tubulointerstitial damage
characterized by cortical and medullary tubular atrophy,
interstitial volume expansion, interstitial mononuclear
cell accumulation, and fibrosis (Fig. 1). By semiquanti-
tative analysis, tubular injury and interstitial inflamma-
tion were similar in obstructed kidneys from the C6+
and C6− groups (Table 1). By quantitative morphomet-
ric analysis, interstitial volume expansion, the number of
vimentin-positive tubules, and interstitial monocyte (ED-
1 positive) cell accumulation in obstructed kidneys were
also similar in the C6+ and C6− groups (Fig. 4). The num-
ber of cortical tubular epithelial cells positive for PCNA
increased in C6+ obstructed kidneys, peaking on days 3
and 6, and this was not significantly altered in C6-deficient
animals (Table 1).
Interstitial myofibroblast and extracellular matrix pro-
tein accumulation. The number of interstitial myofibrob-
lasts increased in obstructed kidneys of C6+ rats, peaking
on day 6, but falling thereafter on days 14 and 24, although
not reaching baseline levels (Fig. 4). In contrast, in ob-
structed kidneys from C6− rats there was a trend toward
an earlier peak in myofibroblast accumulation (day 3 vs.
day 6; P = 0.05 when compared to C6+ day 3) (Fig. 4).
By semiquantive analysis of trichrome-stained sec-
tions, interstitial fibrosis increased progressively in ob-
structed kidneys from C6+ rats, and this was not altered
by C6 deficiency (Table 1). The deposition of specific
interstitial matrix proteins increased in the kidneys of
obstructed C6+ rats, but the pattern was different de-
pending on the type of matrix protein and compartment
(cortex or medulla). In the cortex, interstitial fibronectin
increased in obstructed kidneys from C6+ rats, peaking
on day 14, and falling at later time points (but not reach-
ing baseline levels) (Fig. 4). In contrast, in the medulla,
interstitial fibronectin increased progressively following
ureteric obstruction (Fig. 4). Interstitial fibronectin depo-
sition, however, was not altered by C6 deficiency in either
the cortex or medulla (Fig. 4). In C6+ rats, interstitial type
IV collagen accumulation peaked on day 6 following ob-
struction, in both the medulla and cortex (Fig. 5). On day
3, in C6-deficient rats, cortical interstitial type IV colla-
gen deposition was higher (C6− 12.2 ± 1.5 vs. C6+ 6.5 ±
0.3%; P < 0.02) (Fig. 4), but there were no differences at
other time points, in either the cortex or medulla.
Cyclosporine nephropathy
Mortality in CsA nephropathy. Rats with CsA
nephropathy gained less weight than those in the control
group (Table 2). Survival rates for C6+ and C6− rats with
CsA nephropathy differed. No animals died in the day 14
groups, but after this time point mortality rate increased,
predominantly in the C6− group. By day 35, the percent-
age surviving for the C6+ and C6− groups was 88.9% and
44.4%, respectively (P < 0.001) (Fig. 5). Death in animals
was preceded by progressive weight loss without obvious
clinical neurotoxicity, and at autopsy, rats were cachexic
and there was macroscopic evidence of hepatic injury, but
no other abnormal findings. There was no mortality in the
control C6+ group.
CsA trough levels, renal function, and proteinuria. Be-
cause of the increased mortality in the day 35 groups, fur-
ther analysis was restricted to the day 14-time point. At
this time point, serum cyclosporine levels were equivalent
between the C6+ and C6− groups (P = 0.68, Table 2),
verifying that the stimulus for tubulointerstitial injury
was similar in both groups. The serum creatinine and
urea were elevated in rats with CsA nephropathy, and
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d1
d3
d6
d14
d21
C6+/UUO C6+/UUO C6−/UUO
Fig. 1. C5b-9 immunofluorescence (A to E) and tubulointersitial injury (F to O) in the renal cortex of obstructed kidneys from C6+ and C6− rats
with unilateral ureteric obstruction on days 1, 3, 6, 14, and 24 (trichrome, ×400 magnification).
this was exacerbated slightly by C6 deficiency (Table 2).
Proteinuria in both C6+ and C6− rats with CsA
nephropathy was similar to the control group (P = 0.58,
Table 2).
C5b-9 immunofluorescence on day 14. The peritubu-
lar deposition of C5b-9 was increased in rats with CsA
nephropathy compared to the control group (Fig. 6). C5b-
9 was not detected in C6-deficient animals.
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Fig. 2. Time course of kidney-body weight ratio in C6+ () and C6−
() rats with unilateral ureteric obstruction. Data expressed as mean ±
SEM, N = 5 to 6 per group.
Cortical tubulointerstitial injury on day 14. Macro-
scopically, kidneys from rats with CsA nephropathy had a
granular surface, and this appearance was similar in both
the C6+ and C6− groups, as was the kidney:body weight
ratio (Table 2). By light microscopy, cortical tubulointer-
stitial damage in CsA nephropathy was characterized by
focal areas of tubular atrophy with wrinkled and thick-
ened tubular basement membranes (Fig. 6). By quanti-
tative morphometric analysis, there was an increase in
cortical interstitial volume (control: 13.4 ± 1.2, C6+/CsA:
26.4 ± 0.8%, P < 0.01). This was accompanied by a reduc-
tion in cross-sectional tubular diameter (control: 5.02 ±
0.13, C6+/CsA 4.31 ± 0.11 arbitrary units, P < 0.01)
and tubular epithelial cell height (control: 1.62 ± 0.04,
C6+/CsA: 1.29 ± 0.04 arbitrary units, P < 0.01). However,
neither of these parameters was altered by C6 deficiency
(interstitial volume: 24.1±1.2%; tubular diameter: 4.25±
0.11; tubular epithelial cell height: 1.27 ± 0.01 arbitrary
units).
Cortical interstitial monocyte (ED-1 positive) cell ac-
cumulation increased almost 6-fold in the C6+ group with
CsA nephropathy (control: 14.0 ± 1.7, C6+/CsA: 81.7 ±
6.3 cells/hpf; P < 0.01). However, this increase was not
altered by C6 deficiency (C6-/CsA: 83.2 ± 4.6 cells/hpf).
Vimentin-positive tubules and myofibroblast accumula-
tion were not detected on day 14 in either C6+ or C6−
rats with CsA nephropathy.
Streptozotocin-induced diabetes
Morbidity and blood glucose levels. No animals died
in the study. By day 90, rats with STZ-induced dia-
betes had reduced weight gain compared to control and
insulin-treated animals (Table 3). All animals injected
with STZ developed hyperglycemia, as early as 2 days
after induction of the model (Fig. 7). Urinary ketones
were not detected at any time point in diabetic animals.
Hyperglycemia was sustained for the duration of the
study and not significantly different between the C6−
and C6+ groups (Fig. 7). Vehicle-injected animals and
those implanted with insulin-pellets did not develop hy-
perglycemia. However, by day 90, there was a slight in-
crease in the glucose levels in animals implanted with
insulin pellets.
Renal function. On day 90, proteinuria in rats injected
with STZ was similar to the control group (Table 3). Ani-
mals with STZ-induced diabetes had a higher serum cre-
atinine and urea than the control group, but this was not
altered by C6 defiency or insulin treatment (Table 3).
C5b-9 immunofluorescence. In control animals, oc-
casional focal areas of C5b-9 deposition were detected
without any obvious injury to the tubulointerstitium by
light microscopy (Figs. 8 and 9). In C6+ rats with STZ-
induced diabetes, peritubular C5b-9 deposition was in-
creased (Fig. 8). This increase was partly attenuated by
insulin treatment (Fig. 8). C5b-9 was not detected in C6-
deficient animals.
Kidney:body weight ratio. The kidney:body weight ra-
tio increased in rats with STZ-induced diabetes (Table 3),
and this was almost completely prevented by insulin treat-
ment (P < 0.05, Table 3). In contrast, the kidney:body
weight ratio was not altered in C6− diabetic rats com-
pared to the C6+ diabetic group (Table 3).
Cortical tubulointerstitial injury. Cortical tubuloint-
erstitial damage in STZ-induced diabetes was charac-
terized by distal tubular glycogen nephrosis, interstitial
volume expansion (control: 8.6 ± 0.2 C6+/STZ 13.9 ±
0.7% P < 0.05), tubular dilatation (control: 4.93 ± 0.22;
C6+/STZ: 5.47 ± 0.09 arbitrary units; P < 0.05), and
a reduction in cross-sectional tubule cell height (con-
trol: 1.61 ± 0.01; C6+/STZ 1.34 ± 0.04 arbitrary units;
P < 0.05) (Fig. 9). There was no increase in interstitial
monocyte or myofibroblast accumulation in the STZ-
injected animals compared to controls (data not shown).
The tubulointerstitial changes were prevented in STZ-
injected animals implanted with insulin, but not altered
by C6− deficiency (interstitial volume: 14.2 ± 0.5%; tubu-
lar dilatation: 5.46 ± 0.2; tubule cell height: 1.22 ± 0.05).
DISCUSSION
Recent studies from our laboratory have demonstrated
that chronic tubulointerstitial damage was significantly
attenuated in C6-deficient rats with nephrotic glomeru-
lar diseases (puromycin aminonucleoside, remnant kid-
ney models, adriamycin nephropathy) [19, 21, 24]. In this
paper we examined the converse hypothesis that C5b-9 is
not an important mediator of tubulointerstitial damage
in nonproteinuric chronic renal disease. We utilized three
pathophysiologically distinct models of nonproteinuric
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Table 1. Semiquantitive assessment of cortical tubulointerstitial injury in C6+ and C6− rats with unilateral ureteric obstruction
Day 1 Day 3 Day 6 Day 14 Day 21
Tubular injury
C6+ 1.7 ± 0.2 1.7 ± 0.2 2.8 ± 0.3 3.3 ± 0.2 3.8 ± 0.2
C6− 1.8 ± 0.2 2.1 ± 0.2 3.0 ± 0.5 3.3 ± 0.10 3.8 ± 0.2
C6+ vs. C6− (P value) 0.69 0.16 0.66 0.98 0.94
Tubular PCNA cells/mm2
C6+ 26 ± 11 254 ± 147 237 ± 122 56 ± 22 32 ± 8
C6− 14 ± 9 502 ± 70 61 ± 23 38 ± 8 31 ± 13
C6+ vs. C6− (P value) 0.43 0.14 0.19 0.44 0.94
Interstitial inflammation
C6+ 0.9 ± 0.1 0.9 ± 0.1 2.2 ± 0.1 3.2 ± 0.2 3.8 ± 0.1
C6− 0.9 ± 0.1 1.4 ± 0.2 2.3 ± 0.0 3.5 ± 0.2 3.8 ± 0.1
C6+ vs. C6− (P value) 0.88 0.07 0.35 0.32 1.0
Interstitial fibrosis
C6+ 0 ± 0 0 0.8 ± 0.1 2.1 ± 0.2 3.2 ± 0.2
C6− 0 ± 0 0.2 ± 0.1 1.1 ± 0.1 2.4 ± 0.2 3.7 ± 0.6
C6+ vs. C6− (P value) 1.0 0.15 0.11 0.37 0.39
Data presented as mean ± SEM; N = 5 to 6 per group.
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Fig. 3. Time course of tubulointerstitial injury (tubular vimentin expression, interstitial volume expansion, and interstitial ED-1+ cell accumulation)
in the renal cortex (A to C) and medulla (D to F) of obstructed kidneys from C6+ () and C6− () PVG rats with unilateral ureteric obstruction.
Data expressed as mean ± SEM, N = 5 to 6 per group.
chronic renal disease (ureteric obstruction, cyclosporine-
induced nephrotoxicity, and STZ-induced diabetes) to
test this hypothesis. Despite the up-regulation of C5b-
9 on the basolateral membranes of tubules in all three
models, the severity and progression of tubulointerstitial
damage were consistently not altered by C6 deficiency.
These data suggest that, in contrast to proteinuric states,
C5b-9 does not have a significant impact on the progres-
sion of primary nonglomerular chronic renal diseases.
The results of the previous and current studies em-
phasize the vulnerability of TECs to luminal attack from
C5b-9. Cells (such as erythrocytes and endothelial cells)
that are ordinarily exposed to constant attack from C5b-
9 have evolved protective mechanisms, most notably the
constitutive expression of membrane-bound complement
regulatory proteins (such as CD46, CD55, and CD59)
[26]. In contrast, in physiologic states with an intact
glomerular filtration barrier, TECs are not exposed to the
lytic effects of complement in serum, and have not needed
to make such adaptations [27]. As a result, membrane-
bound complement regulatory proteins are conspicu-
ously absent on the brush border of TECs, and this could
theoretically promote luminal attack on TECs by C5b-9
in nephrotic renal diseases, where complement proteins
Rangan et al: C5b-9 and chronic tubulointerstitial disease 499
0
3
6
9
12
Co
rte
x,
 %
1 3 6 14 24
Interstitial α-SMAA
0
3
6
9
12
M
ed
ul
la
, %
1 3 6 14 24
D
Days
E
Days
1 3 6 14 24
0
7
14
21
28
35
1 3 6 14 24
B
0
7
14
21
28
35 Interstitial fibronectin
F
Days
1 3 6 14 24
0
4
8
12
16
20
24
1 3 6 14 24
C
0
4
8
12
16
20
24
Interstitial collagen IV
*
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expressed as mean ± SEM, N = 5 to 6 per group. ∗P < 0.05.
are present in high concentrations in the tubular lumen
[11, 27]. Furthermore, physiologic tubular secretion of
ammonia into the lumen (which is an activator of com-
plement by the alternative complement through the in-
teraction with the thioester of C3), also serves as an ideal
substrate for C5b-9 assembly [11, 13, 36]. Conversely,
membrane-bound complement regulatory proteins are
abundant in peritubular capillaries and interstitial cells
within the tubulointerstitial compartment of the kidney
[26, 27]. Therefore, we predicted (and confirmed in the
present study) that the progression of tubulointerstitial
damage would not be altered by C6 deficiency in nonpro-
teinuric chronic renal disease.
Another mechanism that might determine whether
C5b-9 is pathogenic in chronic tubulointerstitial injury
is the rate of membrane attack complex formation and
its relationship to disease stage. For example, in UUO,
C5b-9 expression peaked only after 14 days of obstruc-
tion, and by this time significant tubulointerstitial injury
was already established. In contrast, luminal C5b-9 for-
mation occurs as early 7 days after induction of protein-
uria in puromycin aminonucleoside nucleoside nephrosis
[19] (at a time when there is minimal tubulointerstitial in-
jury), and continues to be sustained throughout the dis-
ease process for as long as the proteinuria is maintained
[21]. Hence, our data suggest that chronic proteinuria
provides a rapid and efficient method of C5b-9 assem-
bly, as well as an environment that promotes its sublytic
effects.
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Fig. 5. Kaplan-Meier survival curves of C6+ and C6− rats with CsA
nephropathy (day 35 group)(N = 9 per group).
Unilateral ligation of the ureter is a well-established
experimental model of renal tubulointerstitial fibrosis in
rats and mice [37]. It is characterized by sequential patho-
logic changes, which include interstitial inflammatory cell
accumulation, deposition of interstitial matrix, and an
initial wave of TEC proliferation, followed by profound
TEC apoptosis [37]. A variety of soluble mediators, in-
cluding inflammatory and vascoactive mediators (espe-
cially angiotensin II and tumor necrosis factor), as well
as growth factors, mediate tubulointerstitial injury in this
model [36]. Falk et al reported more than 20 years ago
that the peritubular formation of C5b-9 is increased in
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Table 2. Body weight (BW), kidney weight (KW), and renal function in C6+ and C6− groups with CsA nephropathy on day 14
Group N Initial BW g Final BW g KW/BW g/100g CsA trough ng/mL S Cr lmol/L S Ur mmol/L CrCl mL/min Proteinuria mg/d
Control 6 234 ± 7 269 ± 4 0.30 ± 0.01 – 38 ± 1 4 ± 0 1.06 ± 0.09 9 ± 1
C6+/CsA 9 239 ± 2 248 ± 6a 0.32 ± 0.01 4727 ± 159 62 ± 2a 12 ± 0a 0.64 ± 0.05a 9 ± 1
C6−/CsA 9 234 ± 7 242 ± 5a 0.30 ± 0.01 4815 ± 133 74 ± 4a,b 14 ± 1a,b 0.52 ± 0.03a,b 8 ± 1
Abbreviations are: S Cr, serum creatinine; S Ur, serum urea. Data expressed as mean ± SE.
a P < 0.05 compared to control group; b P < 0.05 compared to C6+/CsA group.
C6+/Control C6+/CsA nephropathy C6−/CsA nephropathy
Fig. 6. C5b-9 immunofluorescence (A to C) and tubulointerstitial injury (PAS-stained sections) (D to F) in the renal cortex of C6+ and C6− rats
with cyclosporine nephropathy (day 14) (×400 magnification).
Table 3. Body weight (BW), kidney weight (KW), and renal function in C6+ and C6− groups with STZ-induced diabetes on day 90
Group Initial BW g Final BW g KW/BW g/100g S Cr lmol/L S Ur mmol/L Proteinuria mg/d
Control 307 ± 5 366 ± 8 0.29 ± 0.01 52 ± 3 8.0 ± 0.3 15 ± 1
C6+ 303 ± 3 259 ± 6a 0.47 ± 0.01a 68 ± 2a 9.1 ± 0.4a 14 ± 2
C6+/insulin 299 ± 5 334 ± 9a 0.33 ± 0.01 63 ± 4a 8.6 ± 0.2a 17 ± 2
C6− 309 ± 7 268 ± 9a 0.47 ± 0.01a 70 ± 8a 9.0 ± 0.6a 21 ± 4
Abbreviations are: S Cr, serum creatinine; S Ur, serum urea. Data expressed as mean ± SE.
aP < 0.05 compared to control group
humans with obstructed kidneys, and suggested that it
could have a pathogenic role in tubulointerstitial dam-
age [5]. Consistent with this study, C5b-9 was deposited
on the basement membrane of TECs in C6+ rats with
UUO. Despite this, however, the progression of kidney
weight loss, tubulointerstitial inflammation, and fibrosis
was similar in both C6+ and C6-deficient animals, indi-
cating that C5b-9 has a redundant role in the induction of
both early and chronic tubulointerstitial damage in this
model. While there was a trend toward an earlier but
smaller peak in peritubular myofibroblast accumulation
in C6-deficient animals with UUO, this was transient and
was not accompanied by reductions in interstitial matrix
deposition at later time points. Finally, as discussed ear-
lier, the peak expression of C5b-9 in UUO was maximal
after day 14, suggesting that C5b-9 is probably the seque-
lae of tissue injury, rather than a primary pathogen, under
these circumstances.
To further substantiate our data, we examined two
other models of chronic tubulointerstitial disease, CsA
nephropathy, and STZ-induced diabetes. Chronic CsA
nephrotoxicity is a major complication of solid organ
transplantation, and is characterized by interstitial in-
flammation/fibrosis, tubulointerstitial proliferation, af-
ferent arteriole hyalinization, and tubular atrophy [38,
39]. Intrarenal hypoxia/reperfusion injury has been pro-
posed as a major pathogenetic mechanism in CsA kid-
ney damage [38]. In that regard, the salutary effects of
C6 deficiency in renal ischemia raised a possibility that
C5b-9 could be pathogenic in CsA nephropathy [27]. In
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the present study, despite equivalent serum trough lev-
els of cyclosporine, tubulointerstitial injury (as assessed
by quantitative morphometric analysis) was not altered
by C6 deficiency in CsA nephropathy. Interestingly, re-
nal function was slightly (but significantly) worsened by
C6 deficiency. We suspect that this may be a glomeru-
lar hemodynamic manifestation of the increased sensi-
tivity to CsA toxicity in C6-deficient animals, given that
tubulointerstitial damage was unaltered. In that respect,
there was a significant late mortality in C6-deficient ani-
mals with CsA nephropathy. The mechanism(s) by which
C6 deficiency increases the sensitivity to CsA toxicity
is not clear and requires further investigation. To our
knowledge, there are no data on the interaction between
complement components and the cytochrome P450IIIA4
isoenzyme, which is the major metabolic pathway for CsA
metabolism [38].
The peritubular deposition of C5b-9 is increased in hu-
mans with diabetic nephropathy, suggesting that glucose-
induced tubulointerstitial injury could, at least in part,
be C5b-9–dependent [5, 11]. To address the specific role
of C5b-9 in this type of tubulointerstitial damage, we
induced STZ-induced diabetes in C6+ and C6− rats.
The STZ-diabetic model is most valuable as a tool to
examine the effects of hyperglycemia per se on kid-
ney structure [40–42]. Consistent with previous studies
in our laboratory, proteinuria was not increased in rats
with STZ-induced diabetes [31], and therefore, our find-
ings have no implications for progression of diabetic
nephropathy with proteinuria. In the present study, the
earliest and most remarkable tubulointerstitial abnor-
mality was the presence of distal tubular cell glycogen
nephrosis, which is due to the accumulation of glycogen
beta particles in the epithelial cells [40–42]. This was ac-
companied by increases in the interstitial volume and
tubular diameter, and a decrease in tubular cell height
(which was due to a reduction in brush border). The
changes in the tubulointerstitium were almost completely
prevented by insulin treatment, verifying that they were
the consequence of hyperglycemia, rather than a toxic ef-
fect of streptozotocin. In C6+ diabetic rats, the peritubu-
lar deposition of C5b-9 was increased, and partly atten-
uated with insulin treatment. STZ toxicity is not known
to affect the complement system [43], and this was con-
firmed in our study by the fact that glucose levels were
identical in both C6+ and C6− groups. However, nei-
ther the increase in kidney weight, renal dysfunction, or
tubulointerstitial injury was altered by C6 deficiency in
rats with chronic hyperglycemia. These data suggest that
C5b-9 is not required for glucose-induced tubulointersti-
tial damage. In contrast to our data, Fujita et al reported
that administration of an inhibitor of C5 (K-76) reduced
proteinuria, glomerular C3 deposition, and glomerular
injury in rats with spontaneous diabetes (Otsuka Long-
Evans Tokushima Fatty rat) [44]. The discrepancy with
our study could be explained by: (1) differences in pro-
teinuria, which was absent in our diabetic rats. In the
presence of proteinuria, we postulate that C5b-9 would
play a more significant role in the pathogenesis of tubu-
lointerstitial damage in diabetic nephropathy, similar to
other nephrotic glomerular diseases (as discussed above);
(2) differences in the components of the complement cas-
cade suppressed; and (3) differences in the pathogenesis
of the two animal models.
The origin and mechanisms involved in the assembly
of C5b-9 along the basement membrane of tubules in
chronic tubulointerstitial diseases is not known. Presum-
ably, peritubular C5b-9 formation is due to extravasa-
tion of complement components from interstitial vascular
bed in an inflamed tissue microenvironment, catalyzed
by the C3-convertase activity of damaged parenchymal
cells. Interestingly, in humans, peritubular C5b-9 deposi-
tion is present in a variety of chronic proteinuric renal
diseases, including lupus nephritis, diabetic nephropathy,
and other chronic glomerulonephritides [4–9]. We have
also noted peritubular C5b-9 deposition in the later stages
of rats with Adriamycin nephropathy [24]. The results
of this study indicate that luminal formation of C5b-9 is
more significant than peritubular assembly, and this may
be due to the differential expression of membrane-bound
complement regulatory proteins and/or rate of C5b-9 for-
mation, as discussed above [45, 46]. These hypotheses re-
quire further examination in future studies.
CONCLUSION
The results of this paper demonstrate that, in the ab-
sence of proteinuria, C5b-9 does not have a significant
impact on the progression of tubulointerstitial damage
in rats with unilateral ureteric obstruction, chronic cy-
closporine nephropathy, or chronic hyperglycemia. These
results may be particularly important in determining
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Fig. 8. C5b-9 staining in the renal cortex of kidneys treated with vehicle (control, A), streptozotocin (C6+, B), streptozotocin+insulin (C6+, C)
and streptozotocin (C6−, D) at day 90 (×400 magnification).
Control C6+/STZ C6−/STZ
Fig. 9. Cortical tubulointerstitial injury in the renal cortex of C6+ and C6− rats with streptozotocin-induced diabetes (day 90). The control
(nondiabetic) group received vehicle (×400 magnification).
which subgroups of patients with chronic kidney disease
will potentially benefit from treatments to suppress C5b-9
to reduce progression [23].
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